Buy-side firms are unprepared for new trading mechanisms, costs and increased complexity and should partner with established providers to adapt to an evolved OTC derivatives marketplace, according to research commissioned […]
This content is for registered users only.
Please log in below, or REGISTER HERE to continue reading.